Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study

Overview of attention for article published in Frontiers in oncology, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 18 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 28,430 followers.

📣 Consensus molecular subtype 4 (CMS4)-targeted therapy in primary #coloncancer: A proof-of-concept study 👨‍⚕️👩‍⚕️ Peters NA et al Read here 👉 https://t.co/FWN1Qj7PQ8 #GICsm

13 Sep 2022

Reply Repost Favourite

RT @Dr_Ivanoncologo: ImPACCT study demonstrates the feasibility of mitigating the #aggressive biology of #CMS4 primary #coloncancer with sp…

08 Sep 2022

Reply Repost Favourite

RT @Dr_Ivanoncologo: ImPACCT study demonstrates the feasibility of mitigating the #aggressive biology of #CMS4 primary #coloncancer with sp…

07 Sep 2022

Reply Repost Favourite

RT @Dr_Ivanoncologo: ImPACCT study demonstrates the feasibility of mitigating the #aggressive biology of #CMS4 primary #coloncancer with sp…

07 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.